Olanzapine
Product Images NDC 67296-1915

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Olanzapine (NDC 67296-1915). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg-30s-bottle.jpg (10mg Bottle 30s)

10mg-30s-bottle.jpg (10mg Bottle 30s)
Each tablet contains 10 mg of olanzapine, an antipsychotic medication. The tablets are orally disintegrating and should be stored between 20°C to 25°C (68°F to 77°F). The medication is manufactured by Apotex Inc in Canada and distributed in the US by Apotex Corp. It is important to protect the tablets from light and moisture and dispense them in a tight, light-resistant container. The usual dosage should be followed as per the medication guide included with the product.*
FDA Label Image

10mg-100s-carton.jpg (10mg Carton)

FDA Label Image

15mg-30s-bottle.jpg (15mg Bottle 30s)

15mg-30s-bottle.jpg (15mg Bottle 30s)
This description provides information about a medication called Olanzapine, specifically in the form of orally disintegrating tablets, with each tablet containing 15 mg of the active ingredient. It includes storage instructions to keep the tablets at a temperature range of 20°C to 25°C (68°F to 77°F) with allowances for slight excursions between 15°C to 30°C (59°F to 86°F). The product should be protected from light and moisture and dispensed in a secure, light-resistant container. There is also a mention of the usual dosage and guidance for pharmacists regarding dispensing with a Medication Guide. The text further includes details about the manufacturer, Apotex Inc., based in Toronto, Ontario, Canada, with manufacturing information for Apotex Corp. based in Weston, Florida, USA. The provided NDC number can be used for identification and tracking purposes.*
FDA Label Image

15mg-100s-carton.jpg (15mg Carton)

15mg-100s-carton.jpg (15mg Carton)
This text appears to be describing Olanzapine Orally Disintegrating Tablets, USP manufactured by ApoTEX. These tablets are used for certain medical purposes.*
FDA Label Image

20mg-30s-bottle.jpg (20mg Bottle 30s)

20mg-30s-bottle.jpg (20mg Bottle 30s)
The text provides information about olanzapine tablets containing 20 mg each. It includes storage instructions to keep the tablets at a temperature between 20°C to 25°C, with excursions allowed from 15°C to 30°C, protecting them from light and moisture. The tablets are orally disintegrating and come in a package of 30 tablets. It instructs pharmacists to dispense with a Medication Guide available at www1.apotex.com/products/us. The product is manufactured by Apotex Inc. in Toronto, Ontario, Canada, and intended for distribution by Apotex Corp. in Weston, Florida. It also mentions the National Drug Code (NDC) for the tablets.*
FDA Label Image

20mg-100s-carton.jpg (20mg Carton)

FDA Label Image

5mg-100s-carton.jpg (5mg 100s Carton)

FDA Label Image

5mg-30s-bottle.jpg (5mg Bottle 30s)

5mg-30s-bottle.jpg (5mg Bottle 30s)
Each tablet contains 5 mg of Olanzapine. The tablets should be stored at a temperature between 20°C to 25°C (68°F to 77°F) with excursions allowed from 15°C to 30°C (69°F to 86°F). It is important to protect them from light and moisture. This package contains 30 tablets of Olanzapine Orally Disintegrating Tablets, USP. The product should be dispensed in a tight, light-resistant container. The NDC number is 60505-3275-3. The manufacturer is Apotex Corp. Pharmacist should dispense with a Medication Guide. Additional dosage information is available in the package insert.*
FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.